Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Purchases $13,800.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 5,000 shares of the stock in a transaction on Thursday, September 10th. The stock was acquired at an average cost of $2.76 per share, for a total transaction of $13,800.00. Following the acquisition, the chief executive officer directly owned 662,000 shares in the company, valued at $1,827,120. This represents a 0.76% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Friday, July 31st, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.47 per share, with a total value of $17,350.00.
• On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.44 per share, with a total value of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.04 per share, with a total value of $15,200.00.

Anixa Biosciences Stock Down 2.8%

NASDAQ:ANIX opened at $2.75 on Friday. The firm’s fifty day simple moving average is $3.34 and its 200-day simple moving average is $2.99. The stock has a market cap of $93.56 million, a PE ratio of -8.59 and a beta of 0.51. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). Equities analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in Anixa Biosciences by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares during the last quarter. Prosperity Wealth Management Inc. raised its holdings in Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after acquiring an additional 5,300 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Anixa Biosciences by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after purchasing an additional 7,271 shares during the last quarter. Renaissance Technologies LLC grew its stake in Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 30th. Finally, Weiss Ratings downgraded Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Anixa Biosciences presently has an average rating of “Hold” and a consensus target price of $10.00.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.